Press Releases

Harvard Apparatus Regenerative Technology To Present at Biotech Showcase 2014 and OneMedForum 2014 in San Francisco
CEO David Green To Speak on Company Progress and Goals on January 13, 2014

HOLLISTON, Mass.--(BUSINESS WIRE)--Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will present at Biotech Showcase™ 2014 and OneMedForum 2014, both in San Francisco, on January 13, 2014. David Green, CEO of Harvard Apparatus Regenerative Technology, will provide an overview of the company, its clinical developments and milestones.

The Biotech Showcase 2014 presentation will be at 10:00 am PT that day in the Mission II Room at the Parc 55 Wyndham San Francisco Hotel.

The OneMedForum 2014 presentation will be at 4:30 pm PT the same day at the Westin San Francisco Market Street Hotel. The webcast of that presentation will be available at the following link, and accessible for 90 days:

www.onemedplace.com/forum/webcast

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the InBreathTM Airway Transplant System, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART’s products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Contact:

Harvard Apparatus Regenerative Technology
David Green
President and CEO
dgreen@HARTregen.com
or
Tom McNaughton
CFO
tmcnaughton@HARTregen.com
or
Investor Relations:
Dian Griesel Int’l.
Cheryl Schneider, 212-825-3210
or
Public Relations:
Dian Griesel Int’l.
Susan Forman or Laura Radocaj, 212-825-3210